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ABSTRACT
Introduction: The purpose of this project was to examine criteria derived from evidence-based
pediatric acute asthma exacerbation assessment tools, asthma scores, and the acute asthma
prediction rule validated and utilized in the emergency department and to adapt these criteria for
pediatric primary care.
Method: Three stages of the project included: (1) identification of criteria in a literature review,
(2) validation of the criteria by an expert panel, and (3) adaptation of the criteria in the design of
an assessment tool.
Results: The criteria were validated and adapted in the design of “The Pediatric Acute Asthma
Exacerbation Severity Assessment and Disposition Decision Making Tool for Pediatric Primary
Care.”
Discussion: The adaptation of criteria derived from the evidence and validated by an expert
panel will inform and guide clinicians in assessing severity and support decision making in
determining disposition of pediatric patients presenting with an acute asthma exacerbation in
primary care.

In the past two decades, children 5 to17 years old have had the highest asthma prevalence
rates as well as the highest exacerbation prevalence rates across all ages. In 2011, four million
children less than 18 years old had an exacerbation of which children ages 5 to 17 years old
accounted for 77% in this age group (American Lung Association, 2012). Rapid management
and treatment must be initiated in children with severe to life threatening exacerbations (U.S.
Department of Health and Human Services, 2007). Clinical signs and symptoms are critical to
determining the severity level of an exacerbation in children. The ED management of moderate
to severe acute asthma exacerbations requires an assessment tool to measure the severity of
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asthma in order to provide effective treatment (Van der Windt, Nagelkereke, Bouter, DankerRoelse, & Veerman, 1994). “Given that pulmonary function testing in the preschool children is
often neither feasible nor reliable, many clinical scores of asthma severity have been developed”
(Birken, Parkin, & MacArthur, 2004, p.1177).
Since many pediatric patients also present with acute asthma exacerbations in primary
care settings, there is a need to implement such tools to guide primary care providers. Such
evidence-based asthma assessment tools are imperative to provide guidance for providers in
assessing severity level, initiating treatment and determining disposition of pediatric patients
with an acute asthma exacerbation in primary care. “The ability to quickly and accurately
evaluate acute asthma exacerbation severity is essential for providing appropriate, quality care in
an efficient manner” (O’Connor, Berg, Stack, & Arnold, 2015, p. 1). Furthermore, use of an
evidence-based asthma assessment tool has the potential to increase patient safety, improve
quality of care, and expedite patient flow in the primary care setting. Our purpose was to
describe the validation and adaptation of criteria used in the design of the Pediatric Acute
Asthma Exacerbation Severity Assessment and Disposition Making Tool for Pediatric Primary
Care.
BACKGROUND
There has been great variability in assessing and treating children with an asthma
exacerbation due to the fact that children at different age levels, vary in their clinical
presentation. As Van der Windt et al. (1994) stated, “A single clinical sign will not be very
indicative of asthma severity, but a combination of signs may provide more valid information,
considering the complex relationship between the pathophysiological and the clinical features of
asthma” (p. 636). Additionally, one method for assessing severity of air way obstruction is by
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pulmonary function tests, such as forced expiratory volume at 1 second (FEV1) and peak
expiratory flow. However, young children do not have the capability to perform pulmonary
function testing, especially during an exacerbation. Birken, Parkin, and Macarthur (2004) noted
that clinical scores for determining asthma severity have been developed because of the
significant fact that pulmonary function testing in preschool children is often neither feasible nor
reliable. Most of these scores were designed in an “ad hoc” manner and since children less than
six years of age were unable to perform pulmonary function tests, clinical signs were the
deciding factor in the assessment of acute asthma (Van der Windt et al., 1994). In addition, there
was very little if any information on the clinimetric properties of the scores when it came to
reliability, validity, and responsiveness whether used in clinical practice or clinical trials (Van
der Windt, 2000).
Individual asthma scores assess and measure the severity of asthma in similar ways, but
with specific differences between the scores. Most asthma scores use a scoring system by
assigning points to presenting clinical signs and symptoms. The first systematic review of
asthma scores was completed by Danielle Van der Windt and her colleagues in 1994. Van der
Windt et al. (1994) conducted a review of the literature for clinical asthma scores to assess acute
asthma exacerbations in pre-school children. Their search identified 16 different clinical asthma
scores between 1966 and 1992. These asthma scores were reviewed for: 1) purpose of the score;
2) description of the score; 3) suitability for use in children; 4) inter-observer agreement; 5)
validity; and 6) responsiveness. The results were then placed in three different tables, based on
the application of the asthma score: 1) discriminative purposes, 2) predictive purposes, and 3)
evaluative purposes. Vander der Windt et al. (1994) also noted that most of the asthma scores
were not based on empirical evidence, but designed in an “ad hoc manner, on the basis of face
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validity only” (p. 637). These scores were not formally developed nor tested using specified
performance measures, but created for the purpose of applying a number scoring system to
evaluate respiratory signs and symptoms in an acute asthma exacerbation in pediatric patients.
Based on their results, the authors concluded that the clinical asthma scores were useful
instruments with discriminative and evaluative properties; however, there was insufficient
information to justify the use of one asthma score over another. In addition, the predictive
validity of the asthma scores was also lacking to allow for application in decision making for
discharging or hospitalizing pediatric patients with an acute asthma exacerbation (Van der Windt
et al., 1994).
Another study by Birken et al. (2004) was conducted to evaluate the measurement
properties of asthma severity scores for use in preschool children. These properties included item
development, reliability, validity, responsiveness, and usability. Through a Medline search (1966
to 2002), 10 asthma severity scores (with 19 different clinical variables) were identified for
children less than six years old. The study also identified the asthma severity scores developed
for use in the inpatient setting (three asthma scores), and the scores developed for use in the ED
setting (seven asthma scores). The results showed that the Clinical Assessment Score (CAS) (for
use in the inpatient setting) and the Preschool Respiratory Assessment Measure (PRAM) (for use
in the ED setting) were the two scores with the “most comprehensive assessment of
measurement properties” (Birken et al., 2004, p. 1180). Birken et al. (2004) concluded there is a
need for asthma severity scores that are reliable, valid, and responsive for the evaluation and
treatment of preschool children with asthma, as well as, for outcome measures when scores are
used in clinical trials.
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There are other published studies that have included The Pediatric Respiratory
Assessment Measure (PRAM) and the Acute Asthma Intensity Research Score (AAIRS). These
studies evaluated the clinimetric properties of these asthma scores, for validity, reliability, and
responsiveness. The PRAM was originally studied in ages 3 to 6 year olds and later studied in its
applicability in children ages 2 to 17 years (Ducharme, et al., 2008). The Acute Asthma Intensity
Research Score (AAIRS) is a modification of the PRAM. Scalene muscle retractions in the
PRAM was replaced by visual intercostal and subcostal retractions as well as expiratory phase
prolongation in the AAIRS (Arnold, Saville, Wang, & Hartert, 2012). The other components of
AAIRS are the same as the PRAM including: suprasternal-sternocleidomastoid retractions, air
entry, wheezing, and oxygen saturation on room air. The PRAM and the AAIRS were each
studied for use in the emergency department setting.
Similarly, Ducharme et al. (2008) conducted a prospective cohort study to examine the
validity, responsiveness, and reliability of the Pediatric Respiratory Assessment Measure
(PRAM). Responsiveness was examined to determine if the PRAM can detect clinically
significant changes over time resulting from treatment. In addition, reliability was assessed by
inter-rater agreement of the degree to which a physician and nurse obtained a similar score
independently in the same patient. Their study included children ages 2 to 17 years old with
acute asthma in which 782 patients had the PRAM recorded at triage. To determine the
performance capabilities of the PRAM, the authors also incorporated the expert skills of over
100 nurses and physicians, who were first trained and then performed the PRAM at three
different points during the patients’ visits: triage, after initial bronchodilation, and disposition.
Using disposition as an outcome, Ducharme et al. (2008), were also able to examine the
predictive validity and responsiveness of the PRAM. Moreover, the results of the study showed
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that the PRAM had good internal consistency and inter-rater reliability for all patients and across
all age groups. For this reason, this study was able to validate the PRAM as a reliable pediatric
tool to use in ages 2 to 17 years, which was extended beyond the original study of ages 3 to 6
years. Thus, the PRAM was changed from the “Preschool” to the “Pediatric” Respiratory
Assessment Measure.
The Acute Asthma Intensity Research Score (AAIRS) is a more recent asthma score and
a modified version of the PRAM. Arnold, Saville, Wang, and Hartert (2012) modified the PRAM
by eliminating scalene muscle retractions and substituting visual intercostal and subcostal
retractions as well as expiratory phase prolongation due to the fact that the PRAM developers
had noted that scalene retractions were observed only in 2% of the participants. Arnold, Saville
et al. (2012) noted in their study, that scalene muscle retractions were difficult to visually
observe in their population of children. Arnold, Saville et al. (2012) in their study, assessed
discrimination and responsiveness of the AAIRS in a prospective cohort of children, ages 5 to 17
years old, with acute asthma exacerbation in a pediatric ED. These results were compared to the
PRAM. Observing and identifying clinical signs of intercostal and subcostal retractions and
expiratory phase prolongation were easier than identifying scalene retractions in younger
children. This accounted for a greater range and variability of the AAIRS. The AAIRS
demonstrated discrimination and responsiveness similar to the PRAM to predict the criterion
standard percentage of predicted forced expiratory volume in 1 second (FEV1) (O’Connor, Berg,
Stack, & Arnold, 2015; Arnold, Saville, et al., 2012). O’Connor, Berg, Stack, and Arnold (2015)
conducted another study (including a cohort of 3 to 17 year olds) with the AAIRS and evaluated
interrater reliability of each of the components among physicians, nurse practitioners, nurses, and
respiratory therapists. They found that respiratory therapists versus physicians or nurse
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practitioners had the best total AAIRS intraclass correlation coefficient both before and after
treatment. As result of their study, O’Connor et al. (2015) determined that there is good interrater
reliability for the overall AAIRS evaluation, yet some components had poor interrater reliability
which was attributed to the absence of training with AAIRS. Training prior to administration of
the AAIRS may prove beneficial for interrater reliability and should be considered in future
studies. Overall, the AAIRS and PRAM are two scores that have been studied and validated and
can be used as an assessment tool to evaluate the level of severity of asthma exacerbations in
pediatric patients (Ducharme et al., 2008; Arnold, Saville, et al, 2012). A comparison of the
performance measures, clinical signs and symptoms, and number of scoring components of the
AAIRS and PRAM is presented in Table 1.
Assessment of the severity of an acute exacerbation in children is critical for rapid
treatment of severe and life threatening episodes; however, in the primary care setting,
assessments are completed in a non-standardized manner. Utilizing the best evidence from
current studies, such as those derived with the PRAM and the AAIRS, provides a basis for
building upon the evidence-based asthma severity assessment tools validated and utilized in the
ED and implementing these tools for use in the pediatric primary care practice. Furthermore,
combining the PRAM and AAIRS will allow for application of the assessment tool for a wide
range of ages from as young as 2 years old up to and including 17 years old in the primary care
setting. This is based on the evidence that the PRAM was validated in ages 2 to 17 years old
(Ducharme et al., 2008) and the AAIRS was not validated for ages younger than 5 years (Arnold,
Saville, et al., 2012). Even in later studies, the AAIRS was only validated for ages 3 years and
older (O’Connor et al., 2015). Furthermore, by combining the PRAM and the AAIRS, this leads
to an assessment tool inclusive of eight components of clinical signs and symptoms from both
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the PRAM and the AAIRS. The National Asthma Education and Prevention Program (NAEPP)
(2007) recommends that all clinicians should be fully prepared to manage an asthma
exacerbation and be able to recognize signs and symptoms of severe and life threatening
exacerbations. The need for a standard assessment tool for reliably determining the severity level
of an asthma exacerbation in pediatric patients is paramount for rapid evaluation and treatment
for clinicians both in the ED and primary care setting. However, for children there is no single
assessment tool that appears to be the preferred tool for assessing the severity of an asthma
exacerbation, evaluating response to treatment and predicting hospitalization (U.S. Department
of Health and Human Services, 2007).
Arnold, O’Connor, and Hartert (2015) conducted a study in which the AAIRS
demonstrated predictive validity for admission to the hospital or PICU. Additionally, Arnold,
Gebretsadik, Abramo, Sheller, et al. (2012) initiated the Acute Asthma Severity Assessment
Protocol (AASAP) study to develop an asthma clinical prediction rule in 2010. This development
of the Pediatric Acute Asthma Prediction Rule (APR) for hospitalization was internally validated
as a tool that is specific for providing the information needed for decision making in admitting
pediatric patients to the hospital. The APR was based on the concept of a clinical prediction rule
(CPR), which is a decision-making tool that incorporates two or more variables from the history,
physical exam, or additional tests to predict the probability of an event or intervention in
admitting a patient (Arnold, Gebretsadik, Abramo, Moons, et al., 2014).
Arnold, Gebretsadik, Abramo, Moons, et al. (2014) conducted the APR study with a
prospective cohort of 928 patients, between ages 5 to17 years old, with acute asthma
exacerbations who presented to the ED and who were enrolled between April 2008 and February
2013. Part of their assessment included candidate predictor variables, such as patient
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demographics, patient asthma characteristics, pulmonary exam findings, and measures of lung
function and inflammation (Arnold, Gebretsadik, Abramo, Moons, et al., 2014). These
researchers indicated that this is most likely the first CPR for acute asthma exacerbations. This
study provided modeling and internal validation for an APR for children with acute asthma
exacerbations, between ages 5 to 17 years old. Furthermore, the predictor variables are clinically
accessible and readily available at the time patients present for triage and before treatment. This
information is helpful for providers to use in their practice along with significant patient
characteristics such as: “prevalence of uncontrolled chronic asthma measured with Global
Initiatives for Asthma (GINA) criteria, second-hand smoke exposure, prior PICU admission for
asthma, and reported use of inhaled corticosteroids” (Arnold, Gebretsadik, Abramo, Moons, et
al., 2014, p. 234). Arnold, Gebretsadik, Abramo, Moons, et al. (2014) concluded that the APR
has the potential to not only improve outcome prediction at the time of ED presentation, but may
also improve triage, patient management, and resource utilization.
The lack of a structured process to assess the severity level of an acute exacerbation in
children in the primary care setting has not been addressed in the literature. Although there have
been numerous published studies in pediatric emergency literature, there is a gap in the literature
regarding severity assessment processes in pediatric primary care.
METHODOLOGY
This project describes the evidence regarding asthma scores to assess the severity level of
an acute asthma exacerbation in pediatric patients as these scores are primarily utilized in the
ED. Using this evidence, the project incorporated the design of an evidence-based asthma
severity assessment tool for primary care practice through three specific stages: (1) identification
and selection of criteria based on a review of the literature, (2) validation of the criteria identified
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in the literature review by a panel of content experts, and (3) adaptation of the criteria into an
asthma severity assessment tool to guide clinicians in the pediatric primary care setting.
The criteria for the asthma severity assessment tool were identified through a literature
review that included using Pub Med, Ovid, Cochrane Library, Medline, UpToDate, SCOPUS,
and CINAHL. Through a comprehensive literature search, articles were found on the
management of an acute asthma exacerbation in an emergency room/department or inpatient
setting for pediatric patients. None of these articles included the assessment or treatment for
pediatric patients presenting with an acute asthma exacerbation in the primary care setting.
Articles that were excluded contained information regarding the assessment of severity of acute
asthma exacerbation in adults. Through the literature search, recent studies by Arnold and his
colleagues on assessing the severity of acute asthma exacerbations in children and predicting the
need for hospitalization were found informing asthma hospitalization decision making and
resource utilization for clinicians treating and managing children with acute asthma
exacerbations. The content derived from the literature review for identifying and selecting
criteria was built into a table and designed as a scoring sheet for the expert panel to input their
ratings.
The second stage included validation of the criteria for the asthma severity assessment
tool based on review by a panel of five experts (see Table 2). The selection of the expert panel
was in accordance with the guidelines for validation of content in evidence-based projects as set
forth by the Yale School of Nursing faculty (Lazenby, Dixon, Coviello, & McCorkle, 2014). The
expert panel included one primary care pediatrician, three nurse practitioners (two specializing in
childhood asthma and two certified as asthma educators), and one pediatric pulmonologist.
Validation took place with two rounds of the expert panel review between July and September
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2016. The scoring sheet for the first round included the rating dimensions for whether the
category should be included (labeled “include category?”), “clarity,” and “relevance.” The next
step in this stage included the validation of expert ratings, which is analogous to content
validation of new tools. Calculation of Content Validity Index (CVI) was based on established
procedures as described by Polit, Beck, and Owen (2007). CVI by item (I-CVI) is computed by
the number of experts responding with positive relevance rating divided by the number of
experts, thus reflecting proportion of experts who judge the item to be relevant (Polit, Beck, &
Owen, 2007, p.460). Scale CVI/Average (S-CVI/Ave) is the average of I-CVI across the items of
a scale or tool. Excellent content validity is indicated by I-CVI value of .78 or greater for all
items, as well as S-CVI/Ave value of .90 or greater for the entire scale. Based on the first round,
calculations of I-CVI and S-CVI/Ave values, a second round was needed to reach consensus by
the expert panel. The scoring sheet was revised and included rating dimensions of “clarity,”
“relevance,” and “feasibility.” Subsequently, calculations for I-CVI and S-CVI/Ave values were
completed for the second round.
The design of the asthma severity assessment tool was the third and final stage. The
validated criteria were integrated into an excel spreadsheet and through several versions, an user
friendly assessment tool was developed. In addition, the criteria were organized so as to be used
as an informative guideline for primary care providers during a patient visit. It was intended that
primary care providers would be able to easily use the assessment tool for the purpose of
documentation and tracking information obtained from the assessment and management of
pediatric patients (ages 2 to 17 years old) presenting with an acute asthma exacerbation in the
primary care setting. No Institutional Review Board approval was necessary for this project as it
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was a literature review to develop an evidence-based assessment tool and validated by a panel of
content experts.
RESULTS
Taken together, the criteria identified from the literature review and validated by the
expert panel were incorporated into the design of the Pediatric Acute Asthma Exacerbation
Severity Assessment and Disposition Decision Making Tool for Pediatric Primary Care (Ages 2
years old up to and including 17 years old). Despite the fact that the literature provided no
evidence specific to pediatric primary care, the literature review did reveal that the best evidence
for the assessment of the severity of an acute exacerbation in children supports criteria from the
Pediatric Respiratory Assessment Measure (PRAM) and Acute Asthma Intensity Research Score
(AAIRS). Additional criteria for determining disposition were based on the evidence derived
from studies on The Asthma Prediction Rule (APR).
All five invited experts independently validated the criteria; however, number of
responses varied by item. In the first round, under the dimension of “Relevance,” only 58% of
the items met the goal of I-CVI > .78. In addition, a S-CVI/Ave value of .79 was obtained under
“Relevance,” which was also below the goal of S-CVI/Ave >.90. In short, results from this first
round, including comments from the experts, indicated a need for further explanation for several
of the items. Based on the results of the first round, a second round was conducted. In the rating
sheet used for the second round, several items were revised, “feasibility” was added as a rating
dimension (replacing “include category”), Global Initiatives for Asthma (GINA) was
decomposed into five items to be rated separately, and additional information was provided.
Also, in the section on clinical signs and symptoms, the experts were asked only to rate “scalene”
retractions, as other items of the section had met the goal of I-CVI > .78 agreement in the
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dimension “Relevance.” This was needed because experts rated “scalene” retractions very low
for “Relevance” (I-CVI value of .60) in the earlier round. Additionally, as part of the second
round, a draft of the resulting asthma severity assessment tool was provided to the experts along
with the scoring sheet. Experts were given the option to provide comments on the draft. The
draft of the tool also included detailed information of the GINA Assessment for Symptom
Control on the back side of the page.
Four of the five experts participated in the second round. Due to incomplete responses, a
follow-up inquiry was conducted with some of the experts. These follow-up responses were
added to the final tally of the expert panel scores and are reflected in results reported in Tables 3
and 4. Table 3 provides a comparison of ratings on the dimension of “Relevance” by specific
criteria in Round 1 and 2 of the expert panel review. Table 4 displays a summary of the percent
of items which received I-CVI values > .78 and < .78, and S-CVI/Ave values for both rounds of
the expert panel review. Only about half of the items met the goal of > .78 to be considered
excellent content validity in Round 1, indicating need for some revisions, and an additional
round of review. In Round 2, the percent of the revised set of items with an I-CVI value > .78
was generally increased -- .79, .53, and .68, for clarity, relevance, and feasibility respectively.
All S-CVI/Ave values in Round 1 were less than the goal of > .90 to attain excellent content
validity. In contrast, the S-CVI/Ave values were higher in Round 2 -- .93, .86, and .90,
respectively for clarity, relevance, and feasibility. Thus, “Clarity” and “Feasibility” met the goal
for excellent content validity; whereas, “Relevance” was only slightly below the goal. Overall,
the results from Round 2 of the expert panel review established content validity for inclusion of
items rated by the expert panel, excluding a few items that did not meet the goal. Decisions made
for these items for criteria inclusion were conducted separately.
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In making decisions about the final version of the Pediatric Acute Asthma Exacerbation
Severity Assessment and Disposition Decision Making Tool to be implemented, evidence
obtained through our comprehensive review was integrated with expert ratings, leading to
decisions to retain some criteria, despite not having achieved desired levels for validation. These
criteria included: “Scalene” retractions, “Inspiratory to Expiratory Ratio,” as well as a few items
under “Socially at Risk,” “Patient Information,” and “The GINA Assessment for Symptom
Control.” These criteria were all retained due to the supporting evidence and associated
validation provided in published studies. It is noted that for each criterion in Round 2 that were
accepted despite lower than ideal level, there was disagreement by only one of the four experts.
(With fewer than five experts, only consensus agreement achieves I-CVI of greater than .78.)
Furthermore, a S-CVI/Ave value of .86 for “Relevance” was determined to be sufficient for
moving forward with implementation of the tool for the same reason that the criteria were
derived from evidence in the literature. These results may appear less than fully optimal for
retaining criteria; thus, these criteria will be evaluated further in going forward with the
implementation of the tool in pediatric primary care practice.
In the third stage of the project, the validated criteria were incorporated into the Pediatric
Acute Asthma Exacerbation Severity Assessment and Disposition Decision Making Tool for
Pediatric Primary Care (Ages 2 years old up to and including 17 years old). General information
for date, time of arrival and time of discharge, as well as a form tracking number are requested at
the top portion of the assessment tool. Next, two primary sections were designed. The first
section is designated as the “Assessment for Severity of an Acute Asthma Exacerbation” and
builds on the foundation of evidence from the Acute Asthma Intensity Score (AAIRS) (Arnold,
Saville et al., 2012) and the Pediatric Respiratory Measure (PRAM) (Ducharme et al., 2008). By
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combining the PRAM and the AAIRS, this leads to an assessment tool inclusive of eight
components of clinical signs and symptoms and resulting in a 19 point system for scoring. This
section reflects the evel of severity of an acute exacerbation of a child based on clinical signs and
symptoms upon arrival and after each treatment given in the primary care setting. The first
section also includes a sub-section, “Treatments Administered During Visit,” to collect
information of medications and oxygen administered for each treatment. The second primary
section of the assessment tool is titled, “Determination for Disposition.” This section includes
sub-sections: 1) “Patient Information” and, 2) “Disposition.” Additionally, the “GINA
Assessment of Symptom Control” (with detailed instructions in calculating the level of symptom
control on back page), “Current Medications,” and “Socially at Risk” are found under the subsection of “Patient Information.” Lastly, the criteria of “Disposition” is located at the end of the
assessment tool and includes “Length of Stay” (from less than 30 minutes to > 2 hours) and
“Discharge to: Home, ED, Hospital Admission” (inpatient or Pediatric Intensive Care Unit
(PICU). The primary care providers completing the assessment will be able to enter their
information in the last row. The form is also designed with designated colors for each section
and sub-section. It can be completed by entering information on a hard-copy or digitally and
incorporated into any medical record whether hard-copy or electronic medical record (EMR).
The front and back pages of the Pediatric Acute Asthma Exacerbation Severity Assessment and
Disposition Decision Making Tool for Pediatric Primary Care are shown in Table 5.
DISCUSSION
The literature review indicated there are several asthma scores that have been evaluated
for their performance; however, to date there is no single preferred tool that is utilized in
assessing pediatric patients with an acute exacerbation in either the ED or primary care. Recent
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literature supports the need for a standardized assessment tool to assess the severity of an acute
asthma exacerbation in pediatric patients in the ED. However, these findings can also be
extended to providers in the pediatric primary care setting where a dearth of evidence exist for
assessing the severity level of an acute exacerbation. The purpose of this project was to examine
criteria derived from evidence-based pediatric acute asthma exacerbation assessment tools,
asthma scores, and the acute asthma prediction rule validated and utilized in the emergency
department (ED) and to adapt these criteria for clinical practice in pediatric primary care.
Our results may facilitate the clinical process for rapidly assessing and initiating treatment for an
acute exacerbation in pediatric patients that could be potentially severe or life-threatening in the
primary care setting. This asthma severity assessment tool includes criteria founded on the
evidence from the Acute Asthma Intensity Research Score (AAIRS), Pediatric Respiratory
Assessment Measure (PRAM), and the Pediatric Acute Asthma Prediction Rule for
Hospitalization (APR). The implementation of this assessment tool may promote the effective
management of pediatric asthma patients with an acute asthma exacerbation in the primary care
setting. Overall, this assessment tool has the potential to enhance patient safety, improve quality
of care and expedite patient flow in primary care pediatric settings.
CONCLUSION
Assessing the severity level of an acute asthma exacerbation in children is key to rapid
management and treatment in the primary care setting. The results of this project will inform
primary care providers in improving clinical practice with an evidence-based pediatric asthma
severity assessment tool. The next step will examine primary care providers’ perception of the
feasibility, usability, and acceptability of this evidence-based asthma severity assessment tool in
improving the assessment process for children presenting with an acute asthma exacerbation.
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The implementation of an evidence-based pediatric asthma severity assessment tool is paramount
in meeting the need for a standardized tool for guiding providers in the pediatric primary care
setting. Ultimately, the goal of this evidence-based project is to improve providers’ skills to
facilitate accurate assessment, treatment, and decision-making in the disposition of pediatric
patients with an acute asthma exacerbation in primary care.
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Table 1. Comparison of Asthma Scores
SCORING COMPONENTS
Score
PRAM
AAIRS
Score
PRAM
AAIRS

# of
Range of
Components
Scores
5
0-12
7
0-16
SEVERITY LEVEL
Mild
Moderate
1 to 3
4 to 7
1 to 6
7 to 11

PERFORMANCE MEASURES
Ages (years)
2 to 17
5 to 17

Reliability
X
X

Validity
X
X

Responsiveness Usability
X
X
X

Discriminative Predictive
Ability
Ability
X
X
X
X

Severe
8 to 12
12 to 16

CLINICAL SIGNS AND SYMPTOMS

Score
PRAM
AAIRS

Oxygen
Saturation
X
X

SuprasternalSternocleidoInspiratory to
mastoid
Scalene
Wheezing Expiratory Ratio Air Entry Retractions Retractions
X
X
X
X
X
X
X
X

(References: Ducharme et al., 2008; Arnold, Saville, Wang, & Hartert, 2012)

Intercostal
Retractions

Subcostal
Retractions

X

X
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Table 2. Comparison of Expert Panel Review - Round 1 and 2
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Table 3. Summary of Content Validity Index (CVI) Values of Expert Panel Review Round 1 and 2
EXPERT PANEL REVIEW
ROUND

1

a

2b
I-CVI Value

I-CVI Value
DIMENSIONS
Include
Category?
Clarity
Relevance

> .78

< .78

41%
64%
58%

59%
36%
42%

Feasibility
a

S-CVI/Ave Value
88%
84%
79%

S-CVI/Ave Value

> .78

< .78

79%
53%

21%
47%

93%
86%

68%

32%

90%

In Round 1, 23 items were rated. Of these, 22 were included in the Item-level Content Validity Index (I-CVI) computations and 19 were included

in Scale-level Content Validity Index Average (S-CVI/Ave) computations. I-CVI calculations are based on number responding to each criteria respectively.
b

In Round 2, 21 items were rated. Of these, 19 were included in I-CVI and S-CVI/Ave computations. I-CVI calculations are based on number

responding to each criteria respectively.
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Table 4. Pediatric Acute Asthma Severity Assessment and Disposition Decision Making Tool
PEDIATRIC ACUTE ASTHMA EXACERBATION SEVERITY ASSESSMENT and DISPOSITION DECISION MAKING TOOL
FOR PEDIATRIC PRIMARY CARE (AGES 2 YEARS OLD UP TO AND INCLUDING 17 YEARS OLD)
DATE:
Interval (*Assessment at arrival and
after each treatment)

Arrival (Baseline)

1st Treatment

2nd Treatment

FORM TRACKING #_____

3rd Treatment

Time:
ASSESSMENT FOR SEVERITY OF AN ACUTE ASTHMA EXACERBATION
(References: Acute Asthma Intensity Research Score (AAIRS): Arnold, Saville,
Wang, & Hartert, 2012; Berg, O'Connor, Lescallette, & Arnold, 2015. Pediatric Respiratory Assessment Measure (PRAM): Ducharme, et al., 2008)
COMMENTS

CLINICAL SIGNS/SYMPTOMS:
INTERVAL* (Enter score in each box)

Arrival (Baseline)

1st Treatment

2nd Treatment

3rd Treatment

1) Albuterol Treatments (Solely)

□ Yes □ No

□ Yes □ No

□ Yes □ No

2) Albuterol and Ipratropium Bromide
Treatments

□ Yes □ No

□ Yes □ No

□ Yes □ No

3) Oral Corticosteroid Treatment

□ Yes □ No

□ Yes □ No

□ Yes □ No

4) Oxygen

□ Yes □ No

□ Yes □ No

□ Yes □ No

SpO2 (on room air): 0= ≥ 95%, 1= 92%-94%, 2=
< 92%
Retractions: (0=Absent, 2=Present)
Suprasternal-Sternocleidomastoid (SCM)
Intercostal
Subcostal
Scalene
Auscultation:
Air Entry: 0=Normal, 1=Decreased at bases,
2=Widespread Decrease, 3=Absent or Minimal
Wheezing: 0=Absent, 1=Expiratory,
2=Inspiratory and Expiratory, 3=Audible
without stethoscope
Expiratory Phase (Inspiratory:Expiratory Ratio):
0=Normal, 1:1; 1=Prolonged, 1:2; 2=Severely
Prolonged, ≤ 1:3

OVERALL SCORE
SEVERITY: 1-6 Mild; 7-12 Moderate; 13-18
Severe
Treatments Administered During Visit:

DETERMINATION FOR DISPOSITION (Reference: Pediatric Acute Asthma Prediction Rule (APR): Arnold, Gebretsadik, Moons, Harrell, & Hartert, 2014)
PATIENT INFORMATION:

COMMENTS

Age: _____________ years old
Gender: □ Male □ Female
Race/Ethnicity: □ African American □ White □ Asian □ Hispanic or Latino □ Other ___________
Insurance Status: □ Private □ Public □ Not Insured
Hospitalization(s) in year prior for asthma: □ Yes □ No
PICU Admission(s) in year prior for asthma: □ Yes □ No

Intubated □ Yes □ No

Global Initiatives for Asthma (GINA) Assessment of Symptom (sx) Control in past 4 weeks: (Details on Back Page)

Global Strategy for Asthma Management & Prevention 2016

1) Daytime sx: > 2/wk [Children ≤ 5yrs: Daytime sx more than a few minutes, > 1/wk]: □ Yes □ No
2) Nocturnal Awakenings sx > 1/wk [Children ≤ 5yrs: Any night waking or coughing due to asthma]: □ Yes □ No
3) Activity Limitations: □ Yes □ No
4) Need for Reliever Medication/Albuterol > 2/wk [Children ≤ 5yrs: Reliever Medication > 1/wk]: □ Yes □ No
Level of Asthma Symptom Control (# of Yes): □ Well-Controlled = None; □ Partly Controlled = 1-2; □ Uncontrolled = 3-4
Asthma Exacerbation treatment with oral corticosteroid (in year prior): □ Yes □ No

Current Medications:
Previously Prescribed Inhaled Corticosteroid: □ Yes □ No
Inhaled Corticosteroid Administered or Used Daily in Past 4 Weeks: □ Yes □ Sometimes □ No
Socially at Risk: □ Unsafe housing □ Homeless shelter □ Parent/Guardian unable to provide care;
Exposures: □ Smoking □ Pets □ Roaches □ Mold □ Other____________________________________
DISPOSITION:

COMMENTS

Length of Stay: □ 0 - 30 minutes □ 30 minutes to 1 hr □ 1 to 2 hrs □ > 2hrs
Discharge to: □ Home □ Emergency Department; Hospital Admission: □ Yes □ No If Yes: □ Inpatient □ PICU

Provider's Name/Date (Completed Assessment):

Discharge Time: __________________
(Updated: 4 March 2017)

28
(Back Page)
DETAILS FOR PATIENT CHARACTERISTICS USING THE GLOBAL INITIATIVE FOR ASTHMA
In 1989, the National Asthma Education and Prevention Program (NAEPP) was originally started to
address the growing problem of asthma in the United States under the National Heart, Lung, and Blood
Institute (NHLBI). In 1993, the National Heart, Lung, and Blood Institute (NHLBI) collaborated with the
World Health Organization (WHO) and produced a report that led to the establishment of the Global
Initiative for Asthma (GINA) to treat and manage asthma as a global health problem for all ages. Both
programs provide evidence-based guidelines for the treatment and management of asthma. Dr. Donald
Arnold incorporated the GINA Strategy for Asthma Management and Prevention 2014 in his studies for
identifying patient characteristics in the Asthma Prediction Rule for Hospitalization (Arnold et al., 2014).
GINA Assessment of Asthma Control:
(Global Initiative for Asthma (2016). Global Strategy for Asthma Management and Prevention 2016)
Level of Asthma Symptom Control:
Well-Controlled=None; Partly Controlled=1-2 Yes; Uncontrolled=3-4 Yes
Adults, adolescents, and children 6-11 years old: (Box 2-2, GINA 2016, p. 29)
In the past 4 weeks, has the patient had:
1) Daytime asthma symptoms more than twice/week?
2) Any night waking due to asthma?
3) Reliever needed for symptoms more than twice/week?
4) Any activity limitation due to asthma?
Specific Question for children 6-11 years:
1) Day Symptoms: How often does the child have cough, wheeze, dyspnea, or heavy breathing (number
of times per week or day)? What triggers the symptoms? How are they handled?
2) Night Symptoms: Cough, awakenings, tiredness during the day? (If the only symptom is cough,
consider rhinitis or gastroesophageal reflux disease)
3) Reliever Use: How often is reliever medication used? (check date on inhaler or last prescription).
Distinguish between pre-exercise use (sports) and use for relief of symptoms.
4) Level of Activity: What sports/hobbies/interests does the child have, at school and in their spare time?
5) How does the child’s level of activity compare with their peers or siblings? Try to get an accurate
picture of the child’s day from the child without interruption from the parent/carer.
Children 5 years and younger: (Box 6-4, GINA 2016, p. 105)
In the past 4 weeks, has the child had:
1) Daytime asthma symptoms for more than a few minutes, more than once a week?
2) Night Symptoms: Any night waking or night coughing due to asthma?
3) Any activity limitation due to asthma? (Runs/plays less than other children, tires easily during
walks/playing?)
4) Reliever medication needed more than once a week?
Other risk factors for asthma exacerbations:
- Uncontrolled asthma symptoms
- One or more severe exacerbation in previous year
- The start of the child’s usual ‘flare-up’ season (especially if autumn/fall)
- Exposures: tobacco smoke, indoor or outdoor air pollution; indoor allergens (e.g. house dust mite,
cockroach, pets, mold), especially in combination with viral infection
- Major psychological or socio-economic problems for child or family
- Poor adherence with controller medication or incorrect inhaler technique
- Hospitalizations or PICU admissions for asthma in the year prior to visit, especially if patient required
Intubation

